Milestone Pharmaceuticals (NASDAQ:MIST) Receives “Buy” Rating from HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Thursday, Benzinga reports.

A number of other research analysts also recently weighed in on MIST. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Tuesday, July 14th. Cantor Fitzgerald started coverage on shares of Milestone Pharmaceuticals in a research note on Thursday, August 20th. They issued an “overweight” rating and a $3.00 target price on the stock. Finally, Wells Fargo & Company decreased their price target on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Milestone Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $6.40.

Milestone Pharmaceuticals Stock Up 3.8%

Shares of NASDAQ MIST traded up $0.04 during trading on Thursday, reaching $1.23. 1,295,656 shares of the stock were exchanged, compared to its average volume of 1,863,977. The business’s 50-day moving average price is $1.19 and its 200 day moving average price is $1.45. The company has a market capitalization of $152.51 million, a price-to-earnings ratio of -1.78 and a beta of 0.98. Milestone Pharmaceuticals has a twelve month low of $1.00 and a twelve month high of $3.06. The company has a quick ratio of 7.92, a current ratio of 8.13 and a debt-to-equity ratio of 3.25.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.82 million. As a group, equities analysts forecast that Milestone Pharmaceuticals will post -0.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Strategic Family Wealth Counselors L.L.C. acquired a new stake in shares of Milestone Pharmaceuticals in the 4th quarter valued at approximately $25,000. Eaton Financial Holdings Company LLC acquired a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at about $26,000. Bank of America Corp DE lifted its stake in shares of Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after acquiring an additional 16,044 shares during the period. HighTower Advisors LLC increased its holdings in Milestone Pharmaceuticals by 100.0% in the second quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock worth $27,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Cetera Investment Advisers acquired a new stake in Milestone Pharmaceuticals in the fourth quarter worth $42,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.